Weight Drugs Fuel New Eating Disorder Fears

Weight-loss medications, including GLP-1 drugs such as Ozempic, Wegovy, and Zepbound, are revolutionizing the industry due to their effectiveness in suppressing appetite. However, healthcare providers and those in recovery from eating disorders express alarm over a growing trend: patients using these drugs are experiencing relapses or developing new eating disorders.

Providers report routinely encountering patients who have turned to these medications to achieve extreme weight loss. This surge is fueled by heavy promotion and easy access, often through online platforms where individuals may inaccurately report their health status to obtain prescriptions. The drugs' mechanism of action, which suppresses natural hunger signals, is particularly concerning as it directly interferes with a core aspect of eating disorder treatment.

Major telehealth sites require users to be 18, yet younger teens are obtaining these drugs by misrepresenting their age and weight, or through pediatricians for obesity treatment. A perspective article in the New England Journal of Medicine estimated that over 420,000 people could develop an eating disorder with long-term use of these medications, representing over 1% of users.

Manufacturers like Novo Nordisk and Eli Lilly state that doctors and patients should make informed treatment decisions, while the FDA monitors drug safety. Despite recommendations for routine eating disorder screenings when prescribing GLP-1s, these are not consistently conducted. Patients like Stevee Williams and AJ Jasper recount severe relapses and health crises, with Jasper calling the drugs "anorexic heroin."